Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of
moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up
off drug to assess the incidence and timing of recurrence of disease or documentation of
delayed response to treatment. There will be the option of increasing the treatment duration
up to an additional 6 months beyond the initially scheduled 6 months of treatment, if
clinically indicated, and at the discretion of the investigator.